Heart valve

Foldax Announces Successful First Human Use of Tria Biopolymer Mitral Heart Valve

Retrieved on: 
Mardi, mai 25, 2021
Health, Medical devices, Surgery, Research, Science, Cardiology, Biotechnology, Anatomy, Cardiac surgery, Heart, Mitral valve, Medical specialties, Heart valve, Valvular heart disease, Mitral valve repair, R. Ravi Kumar

Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.

Key Points: 
  • Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.
  • We are excited to be the first center in the world to implant the innovative Tria mitral valve as part of this research study.
  • In this first-in-man procedure, we saw an immediate improvement in the functionality of this patients heart valve once the valve was in place, said Dr. Heimansohn.
  • We thank Dr. Heimansohn and his skilled team at Ascension St. Vincent Hospital for their commitment to advancing cardiovascular medicine by successfully performing the first-in-man Tria mitral valve procedure, said Foldax CEO Frank Maguire.

Global Annuloplasty Rings Market 2021-2025: Focus on the Development of Personalized Annuloplasty Rings and the Development of Biodegradable Annuloplasty Rings - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mai 21, 2021
Medical devices, Health, Cardiac surgery, Medical specialties, Anatomy, Heart, Mitral valve annuloplasty, Mitral valve, Heart valve

b'The "Global Annuloplasty Rings Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe annuloplasty rings market is poised to grow by $28.83 million during 2021-2025, progressing at a CAGR of over 3%\nThe market is driven by the increasing prevalence of heart valve diseases, increasing preference for mitral valve repair over mitral valve replacement, and technological advances.\nThe report on the annuloplasty rings market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • b'The "Global Annuloplasty Rings Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe annuloplasty rings market is poised to grow by $28.83 million during 2021-2025, progressing at a CAGR of over 3%\nThe market is driven by the increasing prevalence of heart valve diseases, increasing preference for mitral valve repair over mitral valve replacement, and technological advances.\nThe report on the annuloplasty rings market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • This is to help companies strategize and leverage all forthcoming growth opportunities.\nThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\n'

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

Retrieved on: 
Mardi, mai 18, 2021
Anatomy, Circulatory system, Heart, Edwards Lifesciences, Percutaneous aortic valve replacement, Aortic valve, Bicuspid aortic valve, Heart valve, Edwards, Cardiac surgery

"With bicuspid aortic valve disease as another anatomical consideration in the treatment of TAVR patients, these SAPIEN 3 data are encouraging and crucial for guiding treatment, particularly for younger patients.

Key Points: 
  • "With bicuspid aortic valve disease as another anatomical consideration in the treatment of TAVR patients, these SAPIEN 3 data are encouraging and crucial for guiding treatment, particularly for younger patients.
  • "\nThe SAPIEN 3 valve builds on Edwards\' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves.
  • These filings, along with important safety information about our products, may be found at edwards.com.\nEdwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation.
  • This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/real-world-data-confirm-excellen...\n'

Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis

Retrieved on: 
Lundi, mai 17, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, Aortic stenosis, Valve replacement, Heart valve, Edwards Lifesciences, Aortic valve repair

b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.

Key Points: 
  • b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.
  • With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve.
  • "This approval strengthens our structural heart portfolio of minimally invasive offerings by providing new options and improvements to treat a life-threatening heart condition.
  • Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk.

Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

Retrieved on: 
Dimanche, avril 25, 2021
Anatomy, Heart, Cardiac surgery, Heart valves, Aortic valve, Bicuspid aortic valve, Heart valve, Aorta, Aortic valve replacement, Pericardial heart valves

The clinical trial protocol employed strict enrollment criteria and passed the pre-clinical review and got approved by the CFDA (now NMPA).

Key Points: 
  • The clinical trial protocol employed strict enrollment criteria and passed the pre-clinical review and got approved by the CFDA (now NMPA).
  • "\nTaurusOne consists of a prosthetic aortic valve, a delivery catheter and a compression loading system.
  • The aortic valve leaflet is made of bovine pericardium and is processed with a proprietary anti-calcification technique.
  • The stent\'s inflow end has an enhanced radial force design, given that China has a large proportion of patients with high aortic valve calcification or bicuspid aortic valves.

Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

Retrieved on: 
Dimanche, avril 25, 2021
Anatomy, Heart, Cardiac surgery, Heart valves, Aortic valve, Bicuspid aortic valve, Heart valve, Aorta, Aortic valve replacement, Pericardial heart valves

The clinical trial protocol employed strict enrollment criteria and passed the pre-clinical review and got approved by the CFDA (now NMPA).

Key Points: 
  • The clinical trial protocol employed strict enrollment criteria and passed the pre-clinical review and got approved by the CFDA (now NMPA).
  • "\nTaurusOne consists of a prosthetic aortic valve, a delivery catheter and a compression loading system.
  • The aortic valve leaflet is made of bovine pericardium and is processed with a proprietary anti-calcification technique.
  • The stent\'s inflow end has an enhanced radial force design, given that China has a large proportion of patients with high aortic valve calcification or bicuspid aortic valves.

Interventional Robotics Startup Moray Medical Boosts Seed Financing to $5.7 Million

Retrieved on: 
Lundi, avril 12, 2021
General Health, Professional services, Technology, Medical devices, Surgery, Science, Cardiology, Nanotechnology, Biotechnology, Finance, Other Technology, Health, Other Science, Cardiac surgery, Medical specialties, Anatomy, Heart, Mitral valve replacement, Mitral valve repair, Mitral valve, Heart valve

b'Moray Medical announced today that it has closed a total of $5.7 million in seed funding, an increase of $2.4 million compared to the initial raise reported on 01/27/2021.

Key Points: 
  • b'Moray Medical announced today that it has closed a total of $5.7 million in seed funding, an increase of $2.4 million compared to the initial raise reported on 01/27/2021.
  • Investors included 415 CAPITAL (lead), Heal Capital, as well as a number of prominent medtech entrepreneurs, such as Fred St. Goar, MD, inventor of the MitralClip\xe2\x84\xa2 transcatheter mitral valve repair (TMVR) system.\nThe company will use the funding to continue development of its CoralTMsystem, an innovative interventional robotics platform powered by microfluidics and an augmented reality (AR) digital user interface.
  • While the Coral platform promises to dramatically simplify a wide range of minimally invasive cardiovascular interventions, Moray Medical is initially focused on the rapidly growing transcatheter mitral valve repair (TMVR) market.\n\xe2\x80\x9cThere is no argument that transcatheter edge-to-edge repair (TEER), or clip therapy, is steadily evolving into the new clinical standard for heart valve repair.
  • However, the intricacy and learning curve required by currently marketed devices means that the overwhelming majority of sick patients are not receiving treatment,\xe2\x80\x9d said Mark Barrish, CEO and Co-Founder of Moray Medical.\n\xe2\x80\x9cOur Coral platform is designed to empower interventionalists at all skill levels not only to carry out these procedures but also to do so in a cost-efficient manner, with the goal of making certain that millions of additional sick patients who cannot be currently treated will get the life-saving intervention they need,\xe2\x80\x9d added Barrish.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412005591/en/\n'

Global Aortic Valve (Tissue/Biological, Mechanical) Market Report 2020-2030: Emerging Economies are Key Opportunities Area for Market Players

Retrieved on: 
Vendredi, avril 9, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Circulatory system, Valvular heart disease, Cardiology, Aortic stenosis, Aortic valve, Valve replacement, Aortic insufficiency, Regurgitation, Heart valve

The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)

Key Points: 
  • The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)
    A key factor leading to the growth of the market is the increasing prevalence of aortic regurgitation and aortic stenosis.
  • When procedure is taken into consideration, the aortic valve market is divided into open surgery and minimally invasive surgery (MIS), between which, the MIS division held the major value share of the market in 2019.
  • Some of the common treatments recommended for aortic stenosis are transcatheter aortic valve treatment and surgical valve replacement.
  • Companies operating in the aortic valve market are focusing widely on business mergers, strategic partnerships, product launches, and trial and approvals for remaining competitive in the domain.

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

Retrieved on: 
Jeudi, avril 8, 2021
Anatomy, Medical specialties, Heart, Cardiac surgery, Valvular heart disease, Heart valves, Cardiology, Heart valve repair, Tricuspid valve, Heart valve, Tricuspid insufficiency, Regurgitation

ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).

Key Points: 
  • ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).
  • The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient's unique anatomy.
  • When those leaflets do not close properly, blood can flow in the reverse direction known as regurgitation forcing the heart to work harder.
  • "This newest generation device further improves cardiologists' ability to safely and effectively repair the tricuspid valve, which historically has been extremely challenging to treat."

Cardio Industry Executive Ed Rieflin Appointed to Chair Vvital Biomed

Retrieved on: 
Mercredi, avril 7, 2021
Medical specialties, Cardiac surgery, Anatomy, Heart, Valvular heart disease, Cardiology, Regurgitation, Mitral valve, Heart valve repair, Mitral insufficiency, Heart valve

MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.

Key Points: 
  • MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.
  • Commenting on the appointment Rieflin said, "Long-term treatment solutions to mitral valve regurgitation are the holy grail of this sector.
  • Vvital CMO, Aram Smolinsky MD, the heart surgeon who introduced mitral valve repair to Israel and inventor of the Vvital solution, further elucidates, "Vvital's procedure immediately repairs the mitral valve regurgitation.
  • Vvital CEO, Nir Golan remarked, "A true industry expert, Ed Rieflin is a great addition to our company.